Abstract
Hyperprolactinemia is one of the common undesirable phenomena of antipsychotic therapy, as it is associated with a number of mental and somatic complications. To date, there are several strategies for the correction of antipsychotics induced hyperprolactinemia, the most evidential basis of which has an addition to the current treatment of partial dopamine agonist — aripiprazole.Other drugs in this group, cariprazine and brexpiprazole, due to a similar mechanism of action with aripiprazole, belong to prolactin-saving drugs. However, their differences in pharmacodynamics may determine features in prolactin effects and attract attention for further study of their prolactin-saving activity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
